HISTORICAL P100 / #74

Sword Health

Digital Health · United States

Historical ranking valuation$4.00BSource snapshot: Jun 19, 2026

Disclosed primary funding in this record

$334.6M

Sum of non-overlapping disclosed USD amounts in confirmed primary financing entries in this record, including separately labeled equity components; not verified lifetime funding. Excludes amounts already included in a later round, announced, reported, database-only, debt, secondary and unclassified events.

7 confirmed primary rounds with disclosed USD amounts · Record through 2026-09-28

THE BUSINESS

Get to know Sword Health.

Sword offers digital health programs for pain and related care, combining AI-guided interactions with clinical professionals. Its current website presents multiple care programs; this description does not independently validate clinical outcomes.

Sword care programs overview ↗Source checked Sep 24, 2026

Valuation history

Valuations reported at the time of each round.

Jun 17, 2025$4B2025 financing (series not issuer-specified) · ConfirmedSource ↗

Jun 4, 2024$3B2024 primary component (series not issuer-specified) · ReportedSource ↗

Jun 4, 2024$3B2024 employee/early-investor secondary component · ReportedSource ↗

Funding history

Funding rounds, debt and other financing events.

10sourced events · record as of 2026-09-28

Original releases support the 2018 seed and separate 2019/2020 Series A components; the $17M series total and $22M cumulative claim are not extra financings. Seed participant names have separate reported citations, not issuer-confirmed lead roles. The 2024 $130M transaction separates into $30M issuer capital and $100M holder sales on the CEO's account. Sword separately disclosed a 2021 $26M secondary. Dates are source observations or explicitly qualified sorting anchors, not authenticated legal closes. This is not an exhaustive financing register or current shareholder list.

Jun 17, 2025LATEST SOURCED

primary

2025 financing (series not issuer-specified)

General Catalyst (lead)

AmountUSD 40,000,000Valuation$4B

Jun 4, 202409

primary

2024 primary component (series not issuer-specified)

Investors undisclosed

The issuer announced $130M combined primary and secondary. Its CEO told TechCrunch that $30M was newly raised by the company; do not add the $100M holder-sale component to issuer capital.

AmountUSD 30,000,000Valuation$3B

Jun 4, 202408

secondary

2024 employee/early-investor secondary component

Investors undisclosed

CEO-attributed $100M sale of existing shares by employees and early investors, not proceeds to Sword Health.

AmountUSD 100,000,000Valuation$3B

Nov 22, 202107

primary

Series D

Sapphire Ventures (lead)

AmountUSD 163,000,000ValuationUndisclosed

Nov 22, 202106

secondary

Secondary Market Round

Investors undisclosed

Sword's own account identifies a separate $26M secondary alongside the $163M Series D; existing-holder sales are not issuer capital.

AmountUSD 26,000,000ValuationUndisclosed

Jun 29, 202105

primary

Series C

General Catalyst (lead)

AmountUSD 85,000,000ValuationUndisclosed

Feb 1, 202104

primary

Series B

Transformation Capital (Todd Cozzens) (lead)

February 1 is issuer publication date; the release retrospectively says the financing followed a January Series B, without a specific legal close date.

AmountUSD 25,000,000ValuationUndisclosed

Feb 27, 202003

primary

Series A (Extension)

Khosla Ventures (lead) · Founders Fund · Green Innovations · Lachy Groom · Vesalius Biocapital · Faber Ventures

February 27 is announcement day, not a verified legal closing day. $17M combines the original $8M and this $9M. Quoted firm representatives are not additional personal subscribers.

AmountUSD 9,000,000ValuationUndisclosed

Apr 16, 201902

primary

Series A

Khosla Ventures (lead)

April 16 is announcement day, not a verified legal closing day. Unnamed angels and returning seed investors are not filled from another round's participant list.

AmountUSD 8,000,000ValuationUndisclosed

Apr 201801

primary

Seed Round

Green Innovations · Vesalius Biocapital III

Issuer retrospectively confirms amount and April 2018; April 1 is a month sorting anchor. Reported participant names have separate citations, not authenticated legal subscribing vehicles or confirmed lead roles. The 2019 year-in-review and later releases are not additional seed events.

Green Innovations · TechCrunch reported seed participants, April 16, 2018 ↗

Vesalius Biocapital III · TechCrunch reported seed participants, April 16, 2018 ↗

AmountUSD 4,600,000ValuationUndisclosed

Financing participants

Investors, lenders and other parties named in funding announcements.

General Catalyst

2025 financing (series not issuer-specified) · Jun 17, 2025 · Lead participant · primary · Confirmed · Confirmed source ↗

Series C · Jun 29, 2021 · Lead participant · primary · Confirmed · Confirmed source ↗

Sapphire Ventures

Series D · Nov 22, 2021 · Lead participant · primary · Confirmed · Confirmed source ↗

Transformation Capital (Todd Cozzens)

Series B · Feb 1, 2021 · Lead participant · primary · Confirmed · Confirmed source ↗